Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Nature medicine

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.
PMID: 26151329
Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b.

No abstract available.

Cite
Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):827doi: 10.1038/nm0715-827b.
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., Lamba, S., Hobor, S., Avallone, A., Valtorta, E., Rospo, G., Medico, E., Motta, V., Antoniotti, C., Tatangelo, F., Bellosillo, B., Veronese, S., Budillon, A., Montagut, C., Racca, P., Marsoni, S., Falcone, A., Corcoran, R. B., Di Nicolantonio, F., Loupakis, F., Siena, S., Sartore-Bianchi, A., & Bardelli, A. (2015). Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature medicine, 21(7), 827. https://doi.org/10.1038/nm0715-827b
Siravegna, Giulia, et al. "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients." Nature medicine vol. 21,7 (2015): 827. doi: https://doi.org/10.1038/nm0715-827b
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. PMID: 26151329.
Copy Download .nbib Format: NLM
Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases.

Cancer cell international

Fassan M, Vianello L, Sacchi D, Fanelli GN, Munari G, Scarpa M, Cappellesso R, Loupakis F, Lanza C, Salmaso R, Mescoli C, Valeri N, Agostini M, D'Angelo E, Lonardi S, Pucciarelli S, Veronese N, Luchini C, Rugge M.
PMID: 30202242
Cancer Cell Int. 2018 Sep 06;18:131. doi: 10.1186/s12935-018-0634-8. eCollection 2018.

BACKGROUND: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC).METHODS: A series of 22 ENE-positive CRCs was considered and three samples per case were selected (the...

Cite
Fassan M, Vianello L, Sacchi D, et al. Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell Int. 2018;18:131doi: 10.1186/s12935-018-0634-8.
Fassan, M., Vianello, L., Sacchi, D., Fanelli, G. N., Munari, G., Scarpa, M., Cappellesso, R., Loupakis, F., Lanza, C., Salmaso, R., Mescoli, C., Valeri, N., Agostini, M., D'Angelo, E., Lonardi, S., Pucciarelli, S., Veronese, N., Luchini, C., & Rugge, M. (2018). Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer cell international, 18131. https://doi.org/10.1186/s12935-018-0634-8
Fassan, Matteo, et al. "Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases." Cancer cell international vol. 18 (2018): 131. doi: https://doi.org/10.1186/s12935-018-0634-8
Fassan M, Vianello L, Sacchi D, Fanelli GN, Munari G, Scarpa M, Cappellesso R, Loupakis F, Lanza C, Salmaso R, Mescoli C, Valeri N, Agostini M, D'Angelo E, Lonardi S, Pucciarelli S, Veronese N, Luchini C, Rugge M. Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell Int. 2018 Sep 06;18:131. doi: 10.1186/s12935-018-0634-8. eCollection 2018. PMID: 30202242; PMCID: PMC6127990.
Copy Download .nbib Format: NLM
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

ESMO open

Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S.
PMID: 29209533
ESMO Open. 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017.

BACKGROUND: BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic spindle poisons on PATIENTS AND METHODS: Patients progressed to or not deemed eligible for standard treatments...

Cite
Cremolini C, Pietrantonio F, Tomasello G, et al. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open. 2017;2(3):e000241doi: 10.1136/esmoopen-2017-000241.
Cremolini, C., Pietrantonio, F., Tomasello, G., Dadduzio, V., Moretto, R., Morano, F., Schirripa, M., Antoniotti, C., Fucà, G., Bergamo, F., Rossini, D., Nichetti, F., Ziampiri, S., Ghidini, M., Marmorino, F., Prisciandaro, M., Falcone, A., De Braud, F., Loupakis, F., & Lonardi, S. (2017). Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO open, 2(3), e000241. https://doi.org/10.1136/esmoopen-2017-000241
Cremolini, Chiara, et al. "Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study." ESMO open vol. 2,3 (2017): e000241. doi: https://doi.org/10.1136/esmoopen-2017-000241
Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open. 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017. PMID: 29209533; PMCID: PMC5703381.
Copy Download .nbib Format: NLM
Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?.

BMC gastroenterology

Tonello M, Nappo F, Vassallo L, Di Gaetano R, Davoli C, Pizzolato E, De Simoni O, Tassinari C, Scapinello A, Pilati P, Loupakis F, Lonardi S, Sommariva A.
PMID: 35012456
BMC Gastroenterol. 2022 Jan 10;22(1):17. doi: 10.1186/s12876-021-02084-x.

BACKGROUND: We report the first case of a patient affected by peritoneal metastases from colon cancer, arising in the context of Lynch syndrome with pathological complete response. The patient was treated with immunotherapy and cytoreductive surgery. This paper discusses...

Cite
Tonello M, Nappo F, Vassallo L, et al. Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. BMC Gastroenterol. 2022;22(1):17doi: 10.1186/s12876-021-02084-x.
Tonello, M., Nappo, F., Vassallo, L., Di Gaetano, R., Davoli, C., Pizzolato, E., De Simoni, O., Tassinari, C., Scapinello, A., Pilati, P., Loupakis, F., Lonardi, S., & Sommariva, A. (2022). Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. BMC gastroenterology, 22(1), 17. https://doi.org/10.1186/s12876-021-02084-x
Tonello, Marco, et al. "Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?." BMC gastroenterology vol. 22,1 (2022): 17. doi: https://doi.org/10.1186/s12876-021-02084-x
Tonello M, Nappo F, Vassallo L, Di Gaetano R, Davoli C, Pizzolato E, De Simoni O, Tassinari C, Scapinello A, Pilati P, Loupakis F, Lonardi S, Sommariva A. Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. BMC Gastroenterol. 2022 Jan 10;22(1):17. doi: 10.1186/s12876-021-02084-x. PMID: 35012456.
Copy Download .nbib Format: NLM
A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study.

Cancers

Procaccio L, Bergamo F, Daniel F, Rasola C, Munari G, Biason P, Crucitta S, Barsotti G, Zanella G, Angerilli V, Magro C, Paccagnella S, Di Antonio V, Loupakis F, Danesi R, Zagonel V, Del Re M, Lonardi S, Fassan M.
PMID: 34680277
Cancers (Basel). 2021 Oct 13;13(20). doi: 10.3390/cancers13205128.

BACKGROUND: First-line decision making is the key to the successful care of mCRC patients and METHODS: A monoinstitutional prospective head-to-head comparison of LB versus (vs.) STB testing was performed in a real-world setting. Selection criteria included: mCRC diagnosis with...

Cite
Procaccio L, Bergamo F, Daniel F, et al. A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers (Basel). 2021;13(20)doi: 10.3390/cancers13205128.
Procaccio, L., Bergamo, F., Daniel, F., Rasola, C., Munari, G., Biason, P., Crucitta, S., Barsotti, G., Zanella, G., Angerilli, V., Magro, C., Paccagnella, S., Di Antonio, V., Loupakis, F., Danesi, R., Zagonel, V., Del Re, M., Lonardi, S., & Fassan, M. (2021). A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers, 13(20), . https://doi.org/10.3390/cancers13205128
Procaccio, Letizia, et al. "A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study." Cancers vol. 13,20 (2021). doi: https://doi.org/10.3390/cancers13205128
Procaccio L, Bergamo F, Daniel F, Rasola C, Munari G, Biason P, Crucitta S, Barsotti G, Zanella G, Angerilli V, Magro C, Paccagnella S, Di Antonio V, Loupakis F, Danesi R, Zagonel V, Del Re M, Lonardi S, Fassan M. A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers (Basel). 2021 Oct 13;13(20). doi: 10.3390/cancers13205128. PMID: 34680277; PMCID: PMC8533756.
Copy Download .nbib Format: NLM
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target.

Cancers

Salvatore L, Calegari MA, Loupakis F, Fassan M, Di Stefano B, Bensi M, Bria E, Tortora G.
PMID: 31717544
Cancers (Basel). 2019 Nov 09;11(11). doi: 10.3390/cancers11111765.

Molecular assessment of colorectal cancer (CRC) is receiving growing attention, beyond RAS and BRAF, because of its influence on prognosis and prediction in cancer treatment. PTEN (phosphatase and tensin homologue), a tumor suppressor, regulating cell division and apoptosis, has...

Cite
Salvatore L, Calegari MA, Loupakis F, et al. PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers (Basel). 2019;11(11)doi: 10.3390/cancers11111765.
Salvatore, L., Calegari, M. A., Loupakis, F., Fassan, M., Di Stefano, B., Bensi, M., Bria, E., & Tortora, G. (2019). PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers, 11(11), . https://doi.org/10.3390/cancers11111765
Salvatore, Lisa, et al. "PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target." Cancers vol. 11,11 (2019). doi: https://doi.org/10.3390/cancers11111765
Salvatore L, Calegari MA, Loupakis F, Fassan M, Di Stefano B, Bensi M, Bria E, Tortora G. PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers (Basel). 2019 Nov 09;11(11). doi: 10.3390/cancers11111765. PMID: 31717544; PMCID: PMC6896095.
Copy Download .nbib Format: NLM
Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.

Cancers

Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ.
PMID: 33065994
Cancers (Basel). 2020 Oct 13;12(10). doi: 10.3390/cancers12102947.

Cetuximab, an IgG1 EGFR-directed antibody, promotes antibody-dependent cell-mediated cytotoxicity. We hypothesized that single-nucleotide polymorphisms (SNPs) in immune regulatory pathways may predict outcomes in patients with metastatic colorectal cancer treated with cetuximab-based regimens. A total of 924 patients were included:...

Cite
Volz NB, Hanna DL, Stintzing S, et al. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020;12(10)doi: 10.3390/cancers12102947.
Volz, N. B., Hanna, D. L., Stintzing, S., Zhang, W., Yang, D., Cao, S., Ning, Y., Matsusaka, S., Sunakawa, Y., Berger, M. D., Cremolini, C., Loupakis, F., Falcone, A., & Lenz, H. J. (2020). Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 12(10), . https://doi.org/10.3390/cancers12102947
Volz, Nico B, et al. "Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients." Cancers vol. 12,10 (2020). doi: https://doi.org/10.3390/cancers12102947
Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020 Oct 13;12(10). doi: 10.3390/cancers12102947. PMID: 33065994; PMCID: PMC7601940.
Copy Download .nbib Format: NLM
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.

The oncologist

Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F.
PMID: 32369650
Oncologist. 2020 Sep;25(9):803-809. doi: 10.1634/theoncologist.2020-0014. Epub 2020 May 20.

BACKGROUND: Few real-world series on the efficacy and safety of anti-programmed cell death protein-1(PD-1)/programmed death ligand-1(PD-L1)-based therapy are available in molecularly unselected patients with poor performance status (PS) and specific types of advanced cancers, because such populations are typically...

Cite
Pietrantonio F, Loupakis F, Randon G, et al. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist. 2020;25(9):803-809doi: 10.1634/theoncologist.2020-0014.
Pietrantonio, F., Loupakis, F., Randon, G., Raimondi, A., Salati, M., Trapani, D., Pagani, F., Depetris, I., Maddalena, G., Morano, F., Corallo, S., Prisciandaro, M., Corti, F., Guarini, V., Bocconi, A., Marra, A., Belli, C., Spallanzani, A., Fassan, M., Lonardi, S., Curigliano, G., Fucà, G., Di Bartolomeo, M., & de Braud, F. (2020). Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. The oncologist, 25(9), 803-809. https://doi.org/10.1634/theoncologist.2020-0014
Pietrantonio, Filippo, et al. "Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden." The oncologist vol. 25,9 (2020): 803-809. doi: https://doi.org/10.1634/theoncologist.2020-0014
Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist. 2020 Sep;25(9):803-809. doi: 10.1634/theoncologist.2020-0014. Epub 2020 May 20. PMID: 32369650; PMCID: PMC7485362.
Copy Download .nbib Format: NLM
[No title available]

Cancers

Graziano F, Fischer NW, Bagaloni I, Di Bartolomeo M, Lonardi S, Vincenzi B, Perrone G, Fornaro L, Ongaro E, Aprile G, Bisonni R, Prisciandaro M, Malkin D, Gariépy J, Fassan M, Loupakis F, Sarti D, Del Prete M, Catalano V, Alessandroni P, Magnani M, Ruzzo A.
PMID: 32722340
Cancers (Basel). 2020 Jul 24;12(8). doi: 10.3390/cancers12082049.

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated

Cite
Graziano F, Fischer NW, Bagaloni I, et al. . Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082049.
Graziano, F., Fischer, N. W., Bagaloni, I., Di Bartolomeo, M., Lonardi, S., Vincenzi, B., Perrone, G., Fornaro, L., Ongaro, E., Aprile, G., Bisonni, R., Prisciandaro, M., Malkin, D., Gariépy, J., Fassan, M., Loupakis, F., Sarti, D., Del Prete, M., Catalano, V., Alessandroni, P., Magnani, M., & Ruzzo, A. (2020). . Cancers, 12(8), . https://doi.org/10.3390/cancers12082049
Graziano, Francesco, et al. "." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082049
Graziano F, Fischer NW, Bagaloni I, Di Bartolomeo M, Lonardi S, Vincenzi B, Perrone G, Fornaro L, Ongaro E, Aprile G, Bisonni R, Prisciandaro M, Malkin D, Gariépy J, Fassan M, Loupakis F, Sarti D, Del Prete M, Catalano V, Alessandroni P, Magnani M, Ruzzo A. . Cancers (Basel). 2020 Jul 24;12(8). doi: 10.3390/cancers12082049. PMID: 32722340; PMCID: PMC7465166.
Copy Download .nbib Format: NLM
QoL is a cool tool.

Annals of oncology : official journal of the European Society for Medical Oncology

Procaccio L, Lonardi S, Loupakis F, Di Maio M.
PMID: 28430888
Ann Oncol. 2017 Aug 01;28(8):2032-2033. doi: 10.1093/annonc/mdx199.

No abstract available.

Cite
Procaccio L, Lonardi S, Loupakis F, et al. QoL is a cool tool. Ann Oncol. 2017;28(8):2032-2033doi: 10.1093/annonc/mdx199.
Procaccio, L., Lonardi, S., Loupakis, F., & Di Maio, M. (2017). QoL is a cool tool. Annals of oncology : official journal of the European Society for Medical Oncology, 28(8), 2032-2033. https://doi.org/10.1093/annonc/mdx199
Procaccio, L, et al. "QoL is a cool tool." Annals of oncology : official journal of the European Society for Medical Oncology vol. 28,8 (2017): 2032-2033. doi: https://doi.org/10.1093/annonc/mdx199
Procaccio L, Lonardi S, Loupakis F, Di Maio M. QoL is a cool tool. Ann Oncol. 2017 Aug 01;28(8):2032-2033. doi: 10.1093/annonc/mdx199. PMID: 28430888.
Copy Download .nbib Format: NLM
The heterogeneous clinical and pathological landscapes of metastatic .

Cancer cell international

Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M.
PMID: 32015690
Cancer Cell Int. 2020 Jan 29;20:30. doi: 10.1186/s12935-020-1117-2. eCollection 2020.

Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing one of the most frequent causes of cancer-related death worldwide. About 8-15% of CRCs harbor a mutation in

Cite
Fanelli GN, Dal Pozzo CA, Depetris I, et al. The heterogeneous clinical and pathological landscapes of metastatic . Cancer Cell Int. 2020;20:30doi: 10.1186/s12935-020-1117-2.
Fanelli, G. N., Dal Pozzo, C. A., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Dal Santo, L., Lonardi, S., Munari, G., Loupakis, F., & Fassan, M. (2020). The heterogeneous clinical and pathological landscapes of metastatic . Cancer cell international, 2030. https://doi.org/10.1186/s12935-020-1117-2
Fanelli, Giuseppe Nicolò, et al. "The heterogeneous clinical and pathological landscapes of metastatic ." Cancer cell international vol. 20 (2020): 30. doi: https://doi.org/10.1186/s12935-020-1117-2
Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. The heterogeneous clinical and pathological landscapes of metastatic . Cancer Cell Int. 2020 Jan 29;20:30. doi: 10.1186/s12935-020-1117-2. eCollection 2020. PMID: 32015690; PMCID: PMC6990491.
Copy Download .nbib Format: NLM
Benefit from anti-EGFRs in .

ESMO open

Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F.
PMID: 30962964
ESMO Open. 2019 Mar 08;4(2):e000489. doi: 10.1136/esmoopen-2019-000489. eCollection 2019.

No abstract available.

Cite
Cremolini C, Benelli M, Fontana E, et al. Benefit from anti-EGFRs in . ESMO Open. 2019;4(2):e000489doi: 10.1136/esmoopen-2019-000489.
Cremolini, C., Benelli, M., Fontana, E., Pagani, F., Rossini, D., Fucà, G., Busico, A., Conca, E., Di Donato, S., Loupakis, F., Schirripa, M., Lonardi, S., Borelli, B., Ongaro, E., Eason, K., Morano, F., Casagrande, M., Fassan, M., Sadanandam, A., de Braud, F., Falcone, A., & Pietrantonio, F. (2019). Benefit from anti-EGFRs in . ESMO open, 4(2), e000489. https://doi.org/10.1136/esmoopen-2019-000489
Cremolini, Chiara, et al. "Benefit from anti-EGFRs in ." ESMO open vol. 4,2 (2019): e000489. doi: https://doi.org/10.1136/esmoopen-2019-000489
Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F. Benefit from anti-EGFRs in . ESMO Open. 2019 Mar 08;4(2):e000489. doi: 10.1136/esmoopen-2019-000489. eCollection 2019. PMID: 30962964; PMCID: PMC6435314.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries